$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Chief Executive Officer & Director
Compensation
$829,800
Chief Financial Officer
Compensation
$915,375
Chief Legal Officer & Corporate Secretary
Chief Medical Officer
President, Chief Operating Officer & Director
Compensation
$825,750
SVice President of R&D Strategy and Operations
Senior Vice President & Global Head of Quality Assurance
Senior Vice President and Head of Technical Operations & Supply Chain
Senior Vice President of Clinical & Medical Affairs
Vice President & Head of Regulatory Affairs
During the last 12 months, insiders have purchased $4.83M and sold $3.53M worth of BCAX shares, resulting in $1.30M of net buying activity.
0
0.00
108.4K
2.25M
-2.3M
-$2.25M
300.0K
4.80M
43.5K
797.08K
+4.0M
+$4.00M
8.0K
30.32K
26.4K
485.45K
-455K
-$455K
0
0.00
0
0.00
+0
+$0
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$4.80M
Cohlhepp Ryan
Director, Officer: President And Coo
$30K
Cohlhepp Ryan
Director, Officer: President And Coo
$1.16M
Hyep Ivan
Officer: Chief Financial Officer
$1.11M
Mazumdar Claire
Director, Officer: Chief Executive Officer
$1.03M
Raben David
Officer: Chief Medical Officer
$230K
Moderately bullish with $1.30M net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
BCAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 09, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.